Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a stable dose and route of methotrexate.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ablynx
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Clinical diagnosis of active rheumatoid arthritis on a stable background of methotrexate (7.5-25 mg weekly).

Exclusion Criteria:

• Any significant health problem other than rheumatoid arthritis

• Any clinically significant laboratory abnormalities

• Any prior use of B cell-depleting therapy